The influence of HCV coinfection on clinical, immunological and virological responses to HAART in HIV-patients
AUTOR(ES)
Carmo, Ricardo A., Guimarães, Mark D.C., Moura, Alexandre S., Neiva, Augusto M., Versiani, Juliana B., Lima, Letícia V., Freitas, Lílian P., Rocha, Manoel Otávio C.
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2008-06
RESUMO
The potential impact of the hepatitis C virus (HCV) on clinical, immunological and virological responses to initial highly active antiretroviral therapy (HAART) of patients infected with human immunodeficiency virus (HIV) is important to evaluate due to the high prevalence of HIV-HCV coinfection. A historical cohort study was conducted among 824 HIV-infected patients starting HAART at a public referral service in Belo Horizonte, Brazil, to assess the impact of HCV seropositivity on appearance of a new AIDS-defining opportunistic illness, AIDS-related death, suppression of viral load, and an increase in CD4-cell count. A total of 76 patients (9.2%) had a positive HCV test, 26 of whom (34.2%) had a history of intravenous drug use. In multivariate analysis, HCV seropositivity was associated with a smaller CD4-cell recovery (RH=0.68; 95% CI [0.49-0.92], but not with progression to a new AIDS-defining opportunistic illness or to AIDS-related death (RH=1.08; 95% CI [0.66-1.77]), nor to suppression of HIV-1 viral load (RH=0.81; 95% CI [0.56-1.17]) after starting HAART. These results indicate that although associated with a blunted CD4-cell recovery, HCV coinfection did not affect the morbidity or mortality related to AIDS or the virological response to initial HAART.
Documentos Relacionados
- Clinical, virological and immunological features of primary HIV-1 infection.
- Syphilitic meningitis in HIV-patients with meningeal syndrome: report of two cases and review
- HCV virological response during treatment of chronic hepatitis C is associated with liver histological Improvement in patients with HCV/HIV co-infection
- Factors associated with clinical, immunological and virological responses in protease-inhibitor-experienced brazilian children receiving highly active antiretroviral therapy containing Lopinavir-Ritonavir
- HIV-HCV coinfection and liver cancer